SAT-3247

Phase 2Small molecule

SSatellos Bioscience, Inc.

SAT-3247 is one of 6 small molecule programs targeting Long-term Follow-up. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long-Term Follow-upEnrolling by invitation

Long-Term Follow-upPhase 2

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Long-Term Follow-up

#DrugCompanyPhaseTrials

SAT-3247

SSatellos Bioscience, Inc.

Phase 2

1 2

EBT-101

EExcision BioTherapeutics

Phase 1

1 3

MB-CART19.1

MMiltenyi Biomedicine GmbH

Preclinical

1 4

MB-CART2019.1

MMiltenyi Biomedicine GmbH

Preclinical

1 5

Hearticellgram-AMI

PPharmicell Co., Ltd.

Preclinical

1 6

MB-CART20.1

MMiltenyi Biomedicine GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Duchenne Muscular Dystrophy

NCT07287189

Clinical

Trials by Indication[1]

Long-term Follow-up1 trial

A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study

Enrolling by invitation·SSatellos Bioscience, Inc.·Phase 2·NCT06867107·10 enrolled

Adult1 trial

First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort

Completed·SSatellos Bioscience, Inc.·Phase 1·NCT06565208·77 enrolled

Duchenne Muscular Dystrophy1 trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients

Recruiting·SSatellos Bioscience, Inc.·Phase 2·NCT07287189·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAT-3247. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAT-3247 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAT-3247. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Satellos Bioscience, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSatellos Bioscience, Inc.

SAT-3247

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Long-term Follow-up1 trial

Adult1 trial

Duchenne Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News